or Try an Advanced Search...

    Technical Analysis for PTCT - PTC Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 34.09 1.55% 0.52
    PTCT closed up 1.55 percent on Friday, July 26, 2024, on 63 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: Aug 1
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical PTCT trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Weak + Overbought Other 0.00%
    Inside Day Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.35%
    Up 3 Days in a Row Strength 0.35%
    Crossed Above 20 DMA Bullish 3.21%
    NR7 Range Contraction 3.21%
    Older End-of-Day Signals for PTCT ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 14 hours ago
    60 Minute Opening Range Breakdown about 15 hours ago
    Up 2% about 19 hours ago
    Gap Up Partially Closed about 19 hours ago
    Gapped Up (Partial) about 19 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    PTCT Chart by TradingView
    Basic chart:

    Profile

    PTC Therapeutics, Inc. Description

    PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Gene Expression Dystrophy Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders

    Is PTCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 25 PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
    Jul 25 Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
    Jul 1 PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
    Jun 28 Biggest stock movers today: PLUG, NKE, DJT, and more
    Jun 28 PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
    Jun 28 PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
    Jun 28 PTC drops as EU panel declines to recommend Translarna marketing renewal
    Jun 28 CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
    Jun 24 PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
    Jun 20 PTC Therapeutics says FDA lifted partial hold on Huntington's disease program
    See more PTCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 42.14
    52 Week Low 17.53
    Average Volume 909,885
    200-Day Moving Average 28.41
    50-Day Moving Average 34.82
    20-Day Moving Average 32.54
    10-Day Moving Average 33.51
    Average True Range 1.48
    RSI (14) 53.49
    ADX 13.76
    +DI 20.34
    -DI 18.31
    Chandelier Exit (Long, 3 ATRs) 31.79
    Chandelier Exit (Short, 3 ATRs) 33.15
    Upper Bollinger Bands 35.03
    Lower Bollinger Band 30.04
    Percent B (%b) 0.81
    BandWidth 15.33
    MACD Line -0.09
    MACD Signal Line -0.32
    MACD Histogram 0.2251
    Fundamentals Value
    Market Cap 2.57 Billion
    Num Shares 75.5 Million
    EPS -8.82
    Price-to-Earnings (P/E) Ratio -3.87
    Price-to-Sales 2.45
    Price-to-Book 1743.27
    PEG Ratio 0.81
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 35.50
    Resistance 3 (R3) 35.50 35.03 35.27
    Resistance 2 (R2) 35.03 34.67 35.03 35.19
    Resistance 1 (R1) 34.56 34.45 34.56 34.56 35.11
    Pivot Point 34.09 34.09 34.09 34.09 34.09
    Support 1 (S1) 33.62 33.73 33.62 33.62 33.07
    Support 2 (S2) 33.15 33.51 33.15 32.99
    Support 3 (S3) 32.68 33.15 32.92
    Support 4 (S4) 32.68